Phreesia, Inc. (NYSE:PHR) General Counsel Sells $28,300.68 in Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 1,238 shares of Phreesia stock in a transaction on Monday, April 15th. The stock was sold at an average price of $22.86, for a total value of $28,300.68. Following the transaction, the general counsel now directly owns 135,621 shares of the company’s stock, valued at $3,100,296.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Phreesia Trading Up 0.7 %

PHR stock traded up $0.16 during trading on Wednesday, reaching $23.16. 383,738 shares of the stock traded hands, compared to its average volume of 522,719. The business’s 50 day moving average price is $24.56 and its 200-day moving average price is $21.23. The firm has a market capitalization of $1.31 billion, a PE ratio of -9.19 and a beta of 0.92. Phreesia, Inc. has a 52-week low of $12.05 and a 52-week high of $34.98. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.78 and a quick ratio of 1.78.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.02. Phreesia had a negative return on equity of 53.33% and a negative net margin of 38.42%. The company had revenue of $95.00 million for the quarter, compared to analysts’ expectations of $93.52 million. During the same quarter in the previous year, the firm posted ($0.72) earnings per share. The firm’s quarterly revenue was up 24.0% on a year-over-year basis. As a group, sell-side analysts forecast that Phreesia, Inc. will post -1.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PHR. JMP Securities lifted their price objective on Phreesia from $28.00 to $30.00 and gave the stock a “market outperform” rating in a report on Thursday, March 21st. Robert W. Baird raised their price target on Phreesia from $30.00 to $31.00 and gave the stock an “outperform” rating in a research report on Monday, March 18th. Needham & Company LLC reissued a “buy” rating and set a $29.00 price target on shares of Phreesia in a research report on Friday, March 15th. Stephens reissued an “overweight” rating and set a $28.00 price target on shares of Phreesia in a research report on Friday, March 22nd. Finally, Truist Financial initiated coverage on Phreesia in a research report on Monday, February 26th. They set a “buy” rating and a $35.00 price target for the company. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.62.

Institutional Trading of Phreesia

Several hedge funds and other institutional investors have recently bought and sold shares of PHR. Brown Advisory Inc. increased its holdings in Phreesia by 22.2% in the fourth quarter. Brown Advisory Inc. now owns 3,950,356 shares of the company’s stock valued at $91,451,000 after buying an additional 716,374 shares during the last quarter. FMR LLC grew its holdings in shares of Phreesia by 8.6% during the third quarter. FMR LLC now owns 7,856,551 shares of the company’s stock valued at $146,760,000 after purchasing an additional 624,456 shares during the last quarter. Rock Springs Capital Management LP grew its holdings in shares of Phreesia by 36.1% during the third quarter. Rock Springs Capital Management LP now owns 1,776,391 shares of the company’s stock valued at $33,183,000 after purchasing an additional 471,391 shares during the last quarter. Norges Bank bought a new position in shares of Phreesia during the fourth quarter valued at approximately $8,199,000. Finally, BlackRock Inc. grew its holdings in shares of Phreesia by 5.8% during the first quarter. BlackRock Inc. now owns 6,359,641 shares of the company’s stock valued at $167,640,000 after purchasing an additional 349,301 shares during the last quarter. 92.10% of the stock is owned by institutional investors.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.